

Agenda

Measure Applications Partnership Clinician Workgroup In-Person Meeting Agenda

December 9-10, 2015
National Quality Forum Conference Center
1030 15th Street NW, 9th Floor, Washington, DC 20005

Remote Participation Instructions:

Streaming Audio Online

- Direct your web browser to: http://nqf.commpartners.com
- Under "Enter a Meeting" type in the meeting number: 101837 for Day 1 and for 377963 for Day 2.
- In the "Display Name" field, type in your first and last names and click "Enter Meeting."

Teleconference

• Dial (888) 802-7237 for workgroup members or (877) 303-9138 for public participants; use conference ID code: **72951586** for Day 1 and **72953205** for Day 2 to access the audio platform.

Accessing Meeting Materials

Go to http://public.qualityforum.org/MAP/Forms/AllItems.aspx and select the MAP Clinician Workgroup folder

Meeting Objectives:

- Review and provide input on measures under consideration for federal programs applicable to clinicians and other eligible professionals
- Finalize input to the MAP Coordinating Committee on measures for use in federal programs
- Identify gaps in measures for federal clinician quality programs

Day 1-December 9, 2015

8:30 am	Breakfast
9:00 am	Welcome, Disclosures of Interest, Review Meeting Objectives Bruce Bagley, Workgroup Chair Eric Whitacre, Workgroup Chair Chris Cassel, CEO, NQF Reva Winkler, Senior Director, NQF Ann Hammersmith, General Counsel, NQF
9:20 am	Pre-Rulemaking Opening Remarks Kate Goodrich, CMS
9:40 am	Overview of Pre-Rulemaking Approach Andrew Lyzenga, Senior Project Manager, NQF

PAGE 2

Poonam Bal, Project Manager, NQF

- Pre-Rulemaking Timeline
- Approach to decision-making
- Deliberations Process
- Instructions for Voting Process

10:00 am Overview of the Medicare Shared Savings Program (MSSP)

Rabia Khan, CMS (MSSP)

Dr. Winkler

10:30 am Break

10:45 am Opportunity for Public Comment on Medicare Shared Savings Program measures under consideration

11:00 pm Pre-Rulemaking Input on the Medicare Shared Savings Program measures under consideration

Marci Nielsen (Lead Discussant) Kate Koplan (Lead Discussant)

- Falls: Screening, Risk-Assessment, and Plan of Care to Prevent Future Falls (MUC ID: MUC15-579)
- Advance Care Plan (MUC ID: MUC15-578)
- PQI 91 Prevention Quality Acute Composite (MUC ID: MUC15-577)
- Prevention Quality Indicators 92 Prevention Quality Chronic Composite (MUC ID: MUC15-576)
- Ischemic Vascular Disease All or None Outcome Measure (Optimal Control) (MUC ID: MUC15-275)

12:00 pm Lunch

12:30 pm Overview of the Merit-Based Incentive Payment System (MIPS) and Physician Compare (PC) Programs

Molly A. MacHarris, CMS (MIPS)

Alesia D. Hovatter, CMS (Physician Compare)

Dr. Winkler

1:15 pm Opportunity for Public Comment- Dermatology measures under consideration

1:30 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Dermatology

Scott Furney (MIPS Lead Discussant)

Stephen Friedhoff (MIPS Lead Discussant)

Bruce W. Sherman (Physician Compare Lead Discussant)

- Non-Melanoma Skin Cancer (NMSC): Biopsy Reporting Time Clinician (MUC ID: MUC15-215)
- NMSC: Biopsy Reporting Time Pathologist (MUC ID: MUC15-216)
- Use Of Mohs Surgery For Superficial Basal Cell Carcinomas On The Trunk (MUC ID: MUC15-178)

PAGE 3

- Use of Mohs Surgery For Squamous Cell Carcinoma In Situ And Keratoacanthoma Type - Squamous Cell Carcinoma on The Trunk that are 1 cm or smaller (MUC ID: MUC15-179)
- Use Of Preventive Screening Protocol For Transplant Patients (MUC ID: MUC15-177)

2:15 pm Break

2:30 pm Opportunity for Public Comment on Eye Care measures under consideration

2:45 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Eye Care

Scott Friedman (MIPS Lead Discussant)

Beth Averbeck (MIPS Lead Discussant)

Robert Krughoff (Physician Compare Lead Discussant)

- Glaucoma Intraocular Pressure (IOP) Reduction (MUC ID: MUC15-372)
- Glaucoma Intraocular Pressure (IOP) Reduction Following Laser Trabeculosplasty (MUC ID: MUC15-374)
- Exudative Age-Related Macular Degeneration: Loss of Visual Acuity (MUC ID: MUC15-379)
- Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity (MUC ID: MUC15-392)
- Diabetic Macular Edema: Loss of Visual Acuity (MUC ID: MUC15-393)
- Corneal Graft Surgery Postoperative improvement in visual acuity to 20/40 or better (MUC ID: MUC15-370)
- Surgery for Acquired Involutional Ptosis: Patients with an improvement of marginal reflex distance (MRD) (MUC ID: MUC15-375)
- Acquired Involutional Entropion: Normalized lid position after surgical repair (MUC ID: MUC15-377)
- Acute Anterior Uveitis: Post-treatment visual acuity (MUC ID: MUC15-394)
- Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells (MUC ID: MUC15-396)
- Chronic Anterior Uveitis: Post-treatment visual acuity (MUC ID: MUC15-397)
- Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells (MUC ID: MUC15-399)

3:45 pm Opportunity for Public Comment on Cancer measures under consideration

4:00 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Cancer measures under consideration

Janis Orlowski (MIPS Lead Discussant)

Constance Dahlin (MIPS Lead Discussant)

Amy Moyer (Physician Compare Lead Discussant)

- Non-Recommended PSA-Based Screening (MUC ID: MUC15-1019)
- Proportion admitted to hospice for less than 3 days (MUC ID: MUC15-415)
- Minimally invasive surgery performed for patients with endometrial cancer (MUC ID: MUC15-452)

- Surgical staging with lymph node removal for any grade 3 and/or myometrial invasion >50% with endometrial cancer (MUC ID: MUC15-459) (Measure removed from consideration by CMS on 12/2/2015)
- Performance of radical hysterectomy in patients with IB1-IIA cervical cancer who undergo hysterectomy (MUC ID: MUC15-465)
- Use of brachytherapy for cervical cancer patients treated with primary radiation with curative intent (MUC ID: MUC15-460)
- Completion of external beam radiation within 60 days for women receiving primary radiotherapy as treatment for locally advanced cervical cancer (LACC) (MUC ID: MUC15-461)
- Postoperative pelvic radiation with concurrent cisplatin-containing chemotherapy with (or without) brachytherapy for patients with positive pelvic nodes, positive surgical margin, and/or positive parametrium (MUC ID: MUC15-466)
- Use of concurrent platinum-based chemotherapy for patients with stage IIB-IV cervical cancer receiving primary radiation therapy (MUC ID: MUC15-463)
- Platin or taxane administered within 42 days following cytoreduction to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer (MUC ID: MUC15-454)
- Intraperitoneal chemotherapy administered within 42 days of optimal cytoreduction to women with invasive stage III ovarian, fallopian tube, or peritoneal cancer (MUC ID: MUC15-450)

4:45 pm Opportunity for Public Comment

5:00 pm Adjourn

Day 2-December 10, 2015

8:00 am

8:30 am Welcome and Recap of Day 1

Bruce Bagley, Workgroup Chair

Eric Whitacre, Workgroup Chair

Breakfast

8:45 am Opportunity for Public Comment on Interventional Radiology measures under consideration

9:00 am Pre-Rulemaking Input on the MIPS and PC measures under consideration- Interventional Radiology

Paul N. Casale (MIPS Lead Discussant)

David J. Seidenwurm (MIPS Lead Discussant)

Rachel Grob (Physician Compare Lead Discussant)

- Rate of adequate percutaneous image-guided biopsy (MUC ID: MUC15-420)
- Efficacy of uterine artery embolization for symptomatic uterine fibroids (MUC ID: MUC15-423)
- Common femoral arterial access site complication (MUC ID: MUC15-424)

- 30 Day Stroke and Death Rate for Symptomatic Patients undergoing carotid stent placement (MUC ID: MUC15-402)
- Patient reported outcomes following ilio-femoral venous stenting (MUC ID: MUC15-411)
- Assessment of post-thrombotic syndrome following ilio-femoral venous stenting (MUC ID: MUC15-412)
- Improvement in the Venous Clinical Severity Score after ilio-femoral venous stenting (MUC ID: MUC15-413)

10:00 am Break

10:15 pm Opportunity for Public Comment on Urogynecology measures under consideration

10:30 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration-Urogynecology

Luther T. Clark (MIPS Lead Discussant)

James Pacala (MIPS Lead Discussant)

Barb Landreth (Physician Compare Lead Discussant)

- Route of hysterectomy (MUC ID: MUC15-437)
- Over-utilization of mesh in the posterior compartment (MUC ID: MUC15-436)
- Testing for uterine disease prior to obliterative procedures (MUC ID: MUC15-439)
- Verification of Intrinsic Sphincter Deficiency prior to transurethral bulking injection (MUC ID: MUC15-434) (Measure removed from consideration by CMS on 12/2/2015)
- Documentation of offering a trial of conservative management prior to fecal incontinence surgery (MUC ID: MUC15-440)
- Documentation of offering a trial of conservative management prior to urgency incontinence surgery (MUC ID: MUC15-441)

11:30 pm Opportunity for Public Comment on Gastroenterology measures under consideration

11:45 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration-Gastroenterology

Diane Padden (MIPS Lead Discussant)

Peter Briss (MIPS Lead Discussant)

Stephanie Glier (Physician Compare Lead Discussant)

- Surveillance endoscopy for dysplasia in Barrett's Esophagus (MUC ID: MUC15-208)
- Surveillance colonoscopy for dysplasia in Ulcerative Colitis (MUC ID: MUC15-221)
- Surveillance colonoscopy for dysplasia in colonic Crohns Disease (MUC ID: MUC15-221)
- Non-selective beta blocker use in patients with esophageal varices (MUC ID: MUC15-209)
- Hepatitis C Virus (HCV)- Sustained Virological Response (SVR) (MUC ID: MUC15-229)
- Hepatitis B vaccination for patients with chronic Hepatitis C (MUC ID: MUC15-220)
- Hepatitis B vaccination for patients with cirrhosis (MUC ID: MUC15-211)
- Hepatitis A vaccination for patients with cirrhosis (MUC ID: MUC15-210)

- Screening endoscopy for varices in patients with cirrhosis (MUC ID: MUC15-251)
- Screening for Hepatoma in patients with Chronic Hepatitis B (MUC ID: MUC15-217)

12:30 pm Lunch

1:00 pm Opportunity for Public Comment on Miscellaneous measures under consideration

1:15 pm Pre-Rulemaking Input on the MIPS and PC measures under consideration- Miscellaneous Topics

Terry Adirim (MIPS Lead Discussant)

Winfred Wu (MIPS Lead Discussant)

Girma Alemu (MIPS Lead Discussant)

Cynthia Pellegrini (Physician Compare Lead Discussant)

- Paired Measure: Depression Utilization of the PHQ-9 Tool; Depression Remission at Six Months; Depression Remission at Twelve Months (MUC ID: MUC15-928)
- PQI 91 Prevention Quality Acute Composite (MUC ID: MUC15-577)
- Prevention Quality Indicators 92 Prevention Quality Chronic Composite (MUC ID: MUC15-576)
- Potential Opioid Overuse (MUC ID: MUC15-1169)
- HIV Screening for Patients with Sexually Transmitted Disease (STD) (MUC ID: MUC15-230)
- New Corneal Injury Not Diagnosed in the Post-Anesthesia Care Unit/Recovery Area (MUC ID: MUC15-296)
- Performance of objective measure of functional hearing status (MUC ID: MUC15-307)
- Patient-Reported Functional Communication (MUC ID: MUC15-313)
- Ischemic Vascular Disease All or None Outcome Measure (Optimal Control) (MUC ID: MUC15-275)

2:00 pm Workgroup Discussion – Gaps in the Clinician program measure sets

2:30 pm Workgroup Discussion – Alignment

- Alignment of clinician measures across clinician programs
- Alignment of clinician measures with measures in hospital and PAC/LTC programs
- 3:00 pm Workgroup discussion Public reporting of clinician measures
- 3:30 pm Opportunity for Public Comment
- 3:45 pm Summary of the MAP Clinician Workgroup pre-rulemaking input
- 4:00 pm Adjourn